- Previous Close
5.82 - Open
6.05 - Bid --
- Ask --
- Day's Range
6.66 - 8.20 - 52 Week Range
3.67 - 9.50 - Volume
260,938 - Avg. Volume
9,206 - Market Cap (intraday)
58.934M - Beta (5Y Monthly) 0.53
- PE Ratio (TTM)
-- - EPS (TTM)
-1.07 - Earnings Date Oct 15, 2024
- Forward Dividend & Yield 1.00 (13.68%)
- Ex-Dividend Date Sep 1, 2022
- 1y Target Est
9.00
Cryo-Cell International, Inc. engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, and kidney disease, ALS, wound healing, auto-immune diseases, multiple sclerosis, Alzheimer's disease, Parkinson's diseases. The company manufactures and sells PrepaCyte CB processing system, a technology used to process umbilical cord blood stem cells. It markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. Cryo-Cell International, Inc. was incorporated in 1989 and is headquartered in Oldsmar, Florida.
www.cryo-cell.com82
Full Time Employees
November 30
Fiscal Year Ends
Sector
Industry
Recent News: CCEL
View More
Performance Overview: CCEL
Trailing total returns as of 10/30/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CCEL
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CCEL
View MoreValuation Measures
Market Cap
58.93M
Enterprise Value
68.54M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.85
Price/Book (mrq)
--
Enterprise Value/Revenue
2.15
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-28.04%
Return on Assets (ttm)
-0.13%
Return on Equity (ttm)
--
Revenue (ttm)
31.84M
Net Income Avi to Common (ttm)
-8.93M
Diluted EPS (ttm)
-1.07
Balance Sheet and Cash Flow
Total Cash (mrq)
2.13M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-4.78M
Research Analysis: CCEL
View MoreCompany Insights: CCEL
CCEL does not have Company Insights